Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: Implications for international dosing guidelines

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3232-3238

  McIlleron, Helen ^a   Rustomje, Roxana ^b   Vahedi, Mahnaz ^c   Mthiyane, Thuli ^b   Denti, Paolo ^a   Connolly, Catherine ^b   Rid, Wasima ^d   Pym, Alexander ^b   Smith, Peter J ^a   Onyebujoh, Philip C ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TUBERCULOSIS;

EID: 84861143535     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05526-11     Document Type: Article

References (40)

1. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
2. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
3. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
4. Burman W, et al. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350-356. (Pubitemid 43209091)
5. Chideya S, et al. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
6. Chigutsa E, et al. 27 June 2011. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob. Agents Chemother. doi:10.1128/AAC.01833-10.
7. Choudhri SH, et al. 1997. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin. Infect. Dis. 25: 104-111. (Pubitemid 27293083)
8. Conte JE, Jr, Lin E, Zhao Y, Zurlinden E. 2002. A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. J. Chromatogr. Sci. 40:113-118. (Pubitemid 35025314)
9. Donald PR, et al. 1997. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156:895-900. (Pubitemid 27396432)
10. East African-British Medical Research and Councils. 1973. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet i:1331-1338.
11. Fox W. 1979. The chemotherapy of pulmonary tuberculosis: a review. Chest 76:785-796.
12. Gumbo T, et al. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201. (Pubitemid 46080051)
13. Gurumurthy P, et al. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-4475. (Pubitemid 39434921)
14. Hawken M, et al. 1993. Increased recurrence of tuberculosis in HIV-1- infected patients in Kenya. Lancet 342:332-337. (Pubitemid 23227562)
15. Horne DJ, et al. 2010. Factors associated with mortality in patients with tuberculosis. BMC Infect. Dis. 10:258.
16. Jindani A, Nunn AJ, Enarson DA. 2004. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364:1244-1251. (Pubitemid 39311345)
17. Loktionov A, et al. 2002. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect. Prev. 26:15-22. (Pubitemid 36087177)
18. McIlleron H, et al. 2007. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J. Antimicrob. Chemother. 60:1398-1401.
19. McIlleron H, et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
20. Millet JP, et al. 2009. Tuberculosis recurrence and its associated risk factors among successfully treated patients. J. Epidemiol. Community Health 63:799-804.
21. Morgan DJ, Bray KM. 1994. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet. 26:292-307. (Pubitemid 24116207)
22. Muñoz-Sellart M, Cuevas LE, Tumato M, Merid Y, Yassin MA. 2010. Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. Int. J. Tuberc. Lung Dis. 14:973-979.
23. Nahid P, et al. 2007. Treatment outcomes of patients with HIV and tuberculosis. Am. J. Respir. Crit. Care Med. 175:1199-1206. (Pubitemid 46855463)
24. Nettles RE, et al. 2004. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin. Infect. Dis. 38:731-736. (Pubitemid 38333871)
25. Oehlert GW. 1992. A note on the delta method. Am. Stat. 46:27-29.
26. Patel KB, Belmonte R, Crowe HM. 1995. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N. Engl. J. Med. 332:336-337.
27. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
28. Peloquin CA, et al. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-925. (Pubitemid 26295240)
29. Perlman DC, et al. 2005. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41:1638-1647. (Pubitemid 41691604)
30. Polasa K, Murthy KJ, Krishnaswamy K. 1984. Rifampicin kinetics in undernutrition. Br. J. Clin. Pharmacol. 17:481-484. (Pubitemid 14055282)
31. Pulido F, et al. 1997. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch. Intern. Med. 157:227-232. (Pubitemid 27058159)
32. Ruslami R, et al. 2006. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 50:822-823. (Pubitemid 43191013)
33. Sahai J, et al. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293. (Pubitemid 27352050)
34. Schaaf HS, et al. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90:614-618. (Pubitemid 40780724)
35. Smythe W, et al. 2012. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56:2091-2098.
36. van Crevel R, et al. 2002. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int. J. Tuberc. Lung Dis. 6:497-502.
37. Vernon A, Burman W, Benator D, Khan A, Bozeman L. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843-1847. (Pubitemid 29251017)
38. Walker K, et al. 2009. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B Crit. Rev. 12:440-472.
39. World Health Organization. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. WHO/CDS/TB/2003.313. World Health Organization, Geneva, Switzerland.
40. Zhu M, et al. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1360 -1367.